How to Help Your Patients Find Ibalizumab in Stock: A Provider's Guide

The Access Challenge Providers Face With Ibalizumab

Writing the prescription is the easy part. Getting ibalizumab (Trogarzo) into the hands—or more accurately, the veins—of your heavily treatment-experienced (HTE) patients with multidrug-resistant HIV-1 (MDR HIV-1) is a multi-step process that requires coordinating across specialty pharmacies, infusion centers, payers, and patient support programs.

This guide provides a structured roadmap for HIV providers and their care teams to navigate the ibalizumab access process efficiently—and to identify where medfinder can remove friction for both practice staff and patients.

Step 1: Confirm Patient Eligibility Before Initiating Access

Before beginning the access process, confirm the patient meets all criteria:

HIV-1 infection (not HIV-2; ibalizumab is indicated for HIV-1 only)

Adult patient (18+ years; not FDA-approved for pediatric use)

Heavily treatment-experienced with documented resistance to 3+ ARV classes (genotypic/phenotypic resistance testing current and on file)

Actively failing current antiretroviral regimen (detectable viral load)

OBR identified with at least one fully active agent to combine with ibalizumab (monotherapy is not recommended)

No known hypersensitivity to ibalizumab-uiyk

Step 2: Engage Thera Patient Support Immediately

The most time-efficient action is to contact Thera Patient Support as soon as you decide to prescribe ibalizumab. Do not wait for the patient to call.

Thera Patient Support: 1-833-238-4372 | trogarzo.com (HCP portal)

They will coordinate:

Benefits verification and payer coverage investigation

Prior authorization submission and management

Specialty pharmacy connection and prescription routing

Co-pay assistance enrollment for commercially insured patients

ADAP program enrollment for uninsured/underinsured patients

Step 3: Submit a Strong Prior Authorization

Most payers require PA for ibalizumab. A well-prepared PA package includes:

Current genotypic and phenotypic resistance test results (HIV-1)

Most recent viral load and CD4+ T-cell count

Complete antiretroviral treatment history with dates, regimens, and reasons for failure/discontinuation

Planned OBR to be used alongside ibalizumab

Medical necessity letter referencing FDA approval indication, Phase 3 trial data (TMB-301), and DHHS HIV Treatment Guidelines

Step 4: Coordinate the Infusion Site

Ibalizumab must be administered every 14 days. Options for infusion site:

In-clinic or hospital infusion center: Most common. Ensure the site has a process for biweekly scheduling and can store or receive ibalizumab from the specialty pharmacy.

Outpatient infusion center: Freestanding infusion centers can often provide ibalizumab infusions if they contract with the patient's specialty pharmacy.

Home infusion: Available through certain specialty pharmacies. Particularly valuable for patients with limited mobility or transportation barriers. Requires adequate venous access at home setting.

If your practice needs to identify an infusion site quickly, medfinder can call infusion providers near your patient to find which ones can accommodate ibalizumab, saving your care coordinator significant time.

Step 5: Monitor and Maintain Consistent Access

Once therapy begins, consistent biweekly dosing is essential. Key monitoring points:

Missed dose protocol: if maintenance dose is delayed 3+ days, re-administer 2,000 mg loading dose before resuming 800 mg q2w.

Track viral load and CD4+ T-cell count per standard HIV monitoring intervals.

Virologic failure definition for most payers: HIV-RNA ≥200 copies/mL at 6 months (24 weeks) of therapy.

Renew PA every 6 months per most payer requirements (e.g., Neighborhood Health Plan of RI, UnitedHealthcare).

For a deeper dive into payer coverage and the clinical landscape, see our companion post: Ibalizumab Access Challenges: What Providers and Prescribers Need to Know in 2026.